Evidence map›Paper›PMID 39487279›Full record

ArticleJournal of thrombosis and thrombolysis2024

Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors.

Anthony Dumas, Navneet Goyal, Madhusoodanan Mottamal, Daniel K Afosah, Rami A Al-Horani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Haemostasis and the Need for Antithrombotics: An Introduction.Handbook of experimental pharmacology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anthony DumasDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA.
Navneet GoyalDepartment of Chemistry, College of Arts and Science, Xavier University of Louisiana, New Orleans, LA, 70125, USA.
Madhusoodanan MottamalDepartment of Chemistry, College of Arts and Science, Xavier University of Louisiana, New Orleans, LA, 70125, USA.
Daniel K AfosahDepartment of Medicinal Chemistry, College of Pharmacy, Virginia Commonwealth University, 23298, Richmond, VA, USA.
Rami A Al-HoraniDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA. ralhoran@xula.edu.ORCID http://orcid.org/0000-0001-9146-2662

Funding

Xavier RCMI Renewal Application-Research Infrastructure CoreU54MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI Megan Knapp · 2019 to 2026
$41.9M
Synthetic glycosaminoglycan mimetics as regulators of megakaryopoiesis and thrombopoiesisR00HL161423 · NHLBI · UNIVERSITY OF NORTH TEXAS · PI Daniel Kwame Afosah · 2024 to 2026
$683k
Inhibitors of Human Factor XIIIa as New AnticoagulantsR16GM149412 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI Rami A Al-Horani · 2023 to 2026
$599k
Synthetic glycosaminoglycan mimetics as regulators of megakaryopoiesis and thrombopoiesisK99HL161423 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI AFOSAH, DANIEL KWAME · 2022 to 2023
$359k
NHLBI NIH HHS K99 HL161423NHLBI NIH HHS K99HL161423NHLBI NIH HHS R00 HL161423NIGMS NIH HHS R16 GM149412NIGMS NIH HHS R16GM149412NIMHD NIH HHS U54 MD007595NIMHD NIH HHS U54MD007595
6 · The paper itself

Abstract

Factor XIIa (FXIIa) is a plasma serine protease within the contact activation pathway. Inhibiting FXIIa could offer a viable therapeutic approach for achieving effective and safer anticoagulation without the bleeding risks that accompany the use of existing anticoagulants. Therefore, we investigated the anticoagulant properties of an amidine-containing molecule (inhibitor 1) to identify a potential lead molecule for subsequent development of FXIIa inhibitors. Results indicated that inhibitor 1 primarily inhibits human FXIIa with an IC

Indexed as

AnticoagulantsFactor XIIaBlood CoagulationBlood ProteinsCatalytic DomainDrug DiscoveryHEK293 CellsHumansModels, MolecularAnticoagulantsBlood ProteinsFactor XIIafactor XIIa inhibitorActive site inhibitorAnticoagulantsAPTTFXIIaThrombosis

Identifiers

PMID39487279
PMCPMC11972553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.